title: Involvement of nitric oxide in pollen-induced biphasic nasal blockage in sensitised guinea pigs.
abstract: We have developed a reproducible allergic rhinitis model showing biphasic nasal blockage on repetitive inhalation challenge with Japanese cedar pollen in sensitised guinea pigs. The role of nitric oxide (NO) in inducing nasal blockage was evaluated with this model. N(omega)-nitro-L-arginine methyl ester (L-NAME), a non-selective NO synthase (NOS) inhibitor, intravenously administered before the challenge, significantly inhibited both early and late nasal blockage by approximately 80% and 50%, respectively. When L-NAME treatment was performed after the challenge, the late response was inhibited by approximately 70%. This inhibition was completely reversed by co-administration of L-arginine. However, aminoguanidine and L-N(6)-(1-iminoethyl)lysine, selective inhibitors of inducible NOS, negligibly influenced the degree of nasal blockage. Meanwhile, the alpha-adrenergic agonist, naphazoline, strongly suppressed both early and late nasal blockage. These results indicate that NO, likely produced by constitutive rather than inducible NOS, plays a major role in the occurrence of biphasic nasal blockage, primarily by inducing vasodilatation.
authors: Department of Pharmacology, Kyoto Pharmaceutical University, 5 Nakauchi, Misasagi, Yamashina, Kyoto 607-8414, Japan.
authors: A
authors: A
authors: Imai
authors: T
authors: T
authors: Nabe
authors: N
authors: N
authors: Mizutani
authors: H
authors: H
authors: Sakurai
authors: H
authors: H
authors: Takenaka
authors: S
authors: S
authors: Kohno
mesh_terms: D000281:Administration, Intranasal; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000485:Allergens / Q000276:immunology; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D006168:Guinea Pigs; D007275:Injections, Intravenous; D008239:Lysine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009278:Naphazoline / Q000494:pharmacology; D015508:Nasal Obstruction / Q000276:immunology* / Q000517:prevention & control; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052247:Nitric Oxide Synthase Type II; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000517:prevention & control; D012912:Sneezing / Q000187:drug effects; D013997:Time Factors
chemical_list: D000316:Adrenergic alpha-Agonists; D000485:Allergens; D004791:Enzyme Inhibitors; D006146:Guanidines; C090663:N(6)-(1-iminoethyl)lysine; D009569:Nitric Oxide; D001120:Arginine; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D009278:Naphazoline; D008239:Lysine; C004479:pimagedine; D019331:NG-Nitroarginine Methyl Ester